Study Summary
This is a Phase 1/2, multicenter, open-label, first-in-human (FIH) study of donor-derived anti-CD33 Chimeric Antigen Receptor (CAR) T cell therapy (VCAR33) in patients with relapsed or refractory Acute Myeloid Leukemia (AML) after human leukocyte antigen (HLA)-matched allogeneic hematopoietic cell transplant (alloHCT).
Want to learn more about this trial?
Request More InfoInterventions
VCAR33BIOLOGICAL
Allogeneic Anti-CD33 Chimeric Antigen Receptor (CAR) T Cell therapy
Study Locations
| Facility | City | State | Country |
|---|---|---|---|
| University of California San Diego Moores Cancer Center | La Jolla | California | United States |
| Stanford Cancer Institute | Stanford | California | United States |
| Miami Cancer Institute | Miami | Florida | United States |
| Winship Cancer Institute Emory University | Atlanta | Georgia | United States |
| The University of Kansas Cancer Center | Fairway | Kansas | United States |
| National Institutes of Health, Clinical Center | Bethesda | Maryland | United States |
| University of Michigan Health | Ann Arbor | Michigan | United States |
| Karmanos Cancer Institute | Detroit | Michigan | United States |
| Masonic Cancer Center, University of Minnesota | Minneapolis | Minnesota | United States |
| Washington University School of Medicine Siteman Cancer Center | St Louis | Missouri | United States |
| John Theurer Cancer Center at Hackensack University Medical Center | Hackensack | New Jersey | United States |
| Icahn School of Medicine at Mount Sinai | New York | New York | United States |
| University Hospitals Seidman Cancer Center | Cleveland | Ohio | United States |
| University of Utah Huntsman Cancer Institute | Salt Lake City | Utah | United States |